一、基本情况介绍

陈哲生，男，教授，博士学位，博士生/硕士生导师，潍坊医学院“潍医学者”，《Recent Patents on anti-cancer Drug Discovery》、《J New Develop Chem (JNDC) 》及《J Can Res Updates》杂志的主编，《Curr Pharm Biotechnol》、《Cancers》及《Molecules》杂志的客座主编，《Chinese Journal of Cancer 》等24个杂志的编委，《Cancer Res 》等190多个杂志的审稿人，North American ABC transporter Association 委员，美国NIH基金、中国NSFC基金、香港RGC基金、波兰NSC基金、新西兰GOT基金、加拿大、荷兰、匈牙利与俄罗斯等多家国际机构的评审专家，环球健康与教育协会会长，参编《The Research and Biology of Cancer》、《ABC Transporters in Drug Resistant Tumors: Resistance of Targeted Anticancer Therapeutics》、《Methods in Molecular Biology, Cytokine Bioassays》、《Anticancer drugs from marine origin》、《Paclitaxel: Pharmacology, Clinical Uses, and Adverse Effect》、《The Research and Biology of Cancer》、《 Methotrexate: Pharmacology, Clinical Uses, and Adverse Effect 》7部教材。 

二、教学工作

承担《药理学》及《临床药理学》教学工作。

三、科研工作

1、主持或参加科研项目（限5项以内）

[1] Nanowaveguide Illuminated Fluorescence Spectoscope for Studying Membrane Protein，NIH Academic Research Enhancement Award (AREA) Program (R15)，R15GM11604，2015-09至2018-08,277.2万元，已结题，主持

[2] Targeting MRP7 to Overcome Drug Resistance for Ovarian Cancer，NIH Academic Research Enhancement Award (AREA) Program (R15)，R15CA143701-01，2010-02至2013-01，171.5万元，已结题，主持

2、代表性论著（限5项以内）

[1] Lei Zhang，Yidong Li，Wang Qianchao，Zhuo Chen *，Xiaoyun Li，Zhuoxun Wu，Chaohua Hu，Liao Dan，Zhang Wei，Chen Zhe-Sheng*.The PI3K subunits,P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer, Molecular Cancer, 2020, 19(1): 10-27.   

[2] Hailin Tang，XiaojiaHuang，Jin Wang，Lu Yang， Yanan Kong，Guanfeng Gao，Lijuan Zhang，Zhe-Sheng Chen*，Xiaoming Xie*.circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer, Molecular Cancer, 2019, 18(1): 23-31.

[3] Shengtao Xu，Hong Yao;Shanshan Luo，Yun-KaiZhang，Dong-Hua Yang，Dahong Li，Guangyu Wang，Mei Hu，Yangyi Qiu，Xiaoming Wu，Hequan Yao，Weijia Xie，Chen Zhe-Sheng*，Xu Jinyi*. A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway, J Med. Chem., 2017, 60(4): 1449-1468. 

[4] Zhi Shi，Amit K.Tiwari，Suneet Shukla，Robert W. Robey，Satyakam Singh，In-Wha Kim，Susan E.Bates; Xingxiang Peng，Ioana Abraham，Suresh V.Ambudkar，Tanaji T.Talele，Li-Wu Fu，Zhe-Sheng Chen*.Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance , Cancer Research, 2011, 71(8): 3029-41.

[5] Chun-ling Dai，Amit K.Tiwari，Chung-Pu Wu，Xiao-dong Su，  Si-Rong Wang，Dong-geng Liu，Charles R. Ashby Jr.，Yan Huang， Robert W.Robey，Yong-ju Liang，Li-ming Chen，Cheng-Jun Shi， Suresh V.Ambudka，Zhe-Sheng Chen*，Li-Wu Fu*. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 , Cancer Research, 2008, 68(19): 7905-14. 

3、授权发明专利（限5项以内）

[1] Chen Zhe-Sheng. Use of phosphodiesterase inhibitors for treating multidrug resistance, 2014-03-18, 美国, US8673914B2. 

4、获得学术奖励（限5项以内）

[1] Award for outstanding contributions to the Chinese Journal of Cancer, The Chinese Journal of Cancer,1/1, 2015.

[2] 美国癌症研究协会年会(AACR) 青年科学家,青年科学家，1/1,2003.